Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Oct 29, 2021

SELL
$132.37 - $176.78 $37,725 - $50,382
-285 Reduced 40.71%
415 $56,000
Q3 2020

Oct 30, 2020

BUY
$17.47 - $24.93 $12,229 - $17,451
700 New
700 $13,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.06B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Banque Cantonale Vaudoise Portfolio

Follow Banque Cantonale Vaudoise and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Banque Cantonale Vaudoise, based on Form 13F filings with the SEC.

News

Stay updated on Banque Cantonale Vaudoise with notifications on news.